🏛️ Verified NIH Record • Updated 2025-12-01
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) (NCT01838512)
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Bristol-Myers Squibb
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Who can join: Review the eligibility criteria below.
Location: Local Institution — Birmingham, Alabama
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (130 Sites)
Showing the first 25 of 130 sites.
- Local Institution — Birmingham, Alabama
- Local Institute — Goodyear, Arizona
- Local Institution - 0023 — Anaheim, California
- Local Institution — Anaheim, California
- Local Institution - 0045 — Burbank, California
- Local Institution — Corona, California
- Local Institution - 0048 — Downey, California
- Local Institution - 0052 — Fountain Valley, California
- Local Institute — Los Angeles, California
- Local Institute — Santa Rosa, California
- Local Institution - 0051 — Santa Rosa, California
- Local Institution — Brooksville, Florida
- Local Institution - 0044 — Fort Lauderdale, Florida
- Local Institution — Jacksonville, Florida
- Local Institute — Valdosta, Georgia
- Local Institution - 0047 — Valdosta, Georgia
- Local Institution — Skokie, Illinois
- Local Institution - 0041 — Springfield, Illinois
- Local Institution - 0058 — Anderson, Indiana
- Local Institution - 0011 — Indianapolis, Indiana
- Local Institution — Indianapolis, Indiana
- Local Institute — Sioux City, Iowa
- Local Institute — Louisville, Kentucky
- Local Institution - 0042 — Louisville, Kentucky
- Local Institution — Lafayette, Louisiana
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.